Oxonic Acid-13C2,15N3 (potassium salt hydrate)

Oxonic acid-13C2,15N3 is intended for use as an internal standard for the quantification of oxonic acid (potassium salt) (Cay-22586) by GC- or LC-MS. Oxonic acid is a uricase inhibitor (IC50 = 0.8 µM) that prevents metabolism and excretion of uric acid. It also inhibits orotate phosphoribosyltransferase (ORPT), reducing OPRT-mediated phosphorylation of 5-fluorouracil (5-FU, Cay-14416) in Yoshida sarcoma cell extracts with an IC50 value of 3.7 µM. Oxonic acid (10-50 mg/kg) decreases the severity of gastrointestinal tract injury and the incidence of diarrhea induced by the 5-FU prodrug tegafur (Cay-26076) and uracil (Cay-26088) without loss of antitumor activity in a rat Yoshida sarcoma model. It has also been used to induce hyperuricemia in rodents. Formulations containing oxonic acid have been used in the treatment of head, neck, lung, pancreatic, gastric, and breast carcinomas.Formal Name: 1,4,5,6-tetrahydro-4,6-dioxo-1,3,5-triazine-4,6-13C2-1,3,5-15N3-2-carboxylic acid, monopotassium salt, hydrate. Synonyms: Allantoxanic Acid-13C2,15N3, Potassium oxonate-13C2,15N3. Molecular Formula: C2[13C]2H2[15N]3O4 . K [XH2O]. Formula Weight: 200.1. Purity: >95%. Formulation: (Request formulation change), A solid. Solubility: Water: slightly soluble. SMILES: O=[13C]([15N]=C(C([O-])=O)[15NH]1)[15NH][13C]1=O.[K+].O. InChi Code: InChI=1S/C4H3N3O4.K.H2O/c8-2(9)1-5-3(10)7-4(11)6-1,,/h(H,8,9)(H2,5,6,7,10,11),,1H2/q,+1,/p-1/i3+1,4+1,5+1,6+1,7+1,,. InChi Key: KAISPCXZDYMVOB-YKHLTIOGSA-M.